Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg sees plenty of upside at Antofagasta, starts at 'buy'

(Sharecast News) - Berenberg has kicked off coverage of Antofagasta with a 'buy' rating, highlighting the "pure-play" benefits of the copper miner which offers "compelling" growth potential. The broker initiated its coverage with a 2,100p target for Antofagasta's share price, representing 25% upside to current levels.

Pure-play copper businesses trade at a premium valuation multiple to their diversified peers, Berenberg said, due to the attractiveness of the copper investment case. What's more, Antofagasta offers "sector-leading EBITDA margins", it said.

"Antofagasta is a FTSE-100-listed pure-play copper miner, which is a rarity, as other miners with copper exposure tend to be diluted by other metals with less compelling market dynamics, and it thus commands a premium multiple," Berenberg said in a note on Thursday.

The broker hailed the miner's Chilean asset base potential, with volumes expected to grow from around 680,000 tonnes in 2025 to 900kt by 2028, helped by the second concentrator project at Centinela and improved grades at its Los Pelambres mine.

"Costs also remain competitive, with c80% of its production sitting in the first quartile of the copper cost curve, and scope for a beat versus cost guidance due to strong by-product prices (ie gold)," Berenberg said.

The broker also said that the market is underestimating Antofagasta's 18.94% stake in Peruvian miner Buenaventura, which provides a lot of upside despite the latter's shares having surged by 56% since the former first invested in 2023.

Antofagasta shares were down 5% at 1,602.5p by 1109 GMT, along with the rest of the mining sector as global financial markets reacted to launch of far-reaching US import tariffs.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.